The neurochemical effects of
adenosine signaling in
small-fiber neuropathy leading to
neuropathic pain are yet to be explored in a direct manner. This study examined this system at the level of
ligand (through the ectonucleotidase activity of
prostatic acid phosphatase [PAP]) and
adenosine A1 receptors (A1Rs) in
resiniferatoxin (RTX) neuropathy, a peripheral
neurodegenerative disorder that specifically affects nociceptive nerves expressing transient receptor potential vanilloid type 1 (TRPV1). We conducted immunohistochemistry on dorsal root ganglion (DRG) neurons, high-performance liquid chromatography for functional assays, and pharmacological interventions to alter PAP and A1Rs in mice with RTX neuropathy. In DRG of RTX neuropathy, PAP(+) neurons were reduced compared with vehicle-treated mice (P = 0.002). Functionally, PAP ectonucleotidase activity was consequently reduced (ie, the content of
adenosine in DRG, P = 0.012). PAP(+) neuronal density was correlated with the degree of
mechanical allodynia, which was reversed by intrathecal (i.t.) lumbar puncture injection of recombinant PAP with a dose-dependent effect. Furthermore, A1Rs were downregulated (P = 0.002), and this downregulation was colocalized with the
TRPV1 receptor (31.0% ± 2.8%).
Mechanical allodynia was attenuated in a dose-dependent response by i.t. injection of the A1R
ligand,
adenosine; however, no
analgesia was evident when an exogenous
adenosine was blocked by A1R antagonist. This study demonstrated dual mechanisms of
neuropathic pain in TRPV1-induced neuropathy, involving a reduced
adenosine system at both the
ligand (
adenosine) and receptor (A1Rs) levels.